within Pharmacolibrary.Drugs.V_Various.V03A_AllOtherTherapeuticProducts.V03AB23_Acetylcysteine;

model Acetylcysteine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.138888888888889e-06,
    adminDuration = 600,
    adminMass = 600 / 1000000,
    adminCount = 1,
    Vd = 0.00047,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0005899999999999999,
    k12 = 1.6333333333333335e-06,
    k21 = 1.6333333333333335e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Acetylcysteine</td></tr><tr><td>ATC code:</td><td>V03AB23</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>600</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.47</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.11</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Acetylcysteine is a mucolytic agent and an antidote used primarily for the treatment of acetaminophen (paracetamol) overdose. It restores hepatic glutathione and protects against liver damage. It is also used to reduce the viscosity of pulmonary secretions in diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis. The drug is approved and in current clinical use, both as oral and intravenous formulations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects following intravenous administration.</p><h4>References</h4><ol><li><p>Forrest, JA, et al., &amp; Prescott, LF (1982). Clinical pharmacokinetics of paracetamol. <i>Clinical pharmacokinetics</i> 7(2) 93–107. DOI:<a href=\"https://doi.org/10.2165/00003088-198207020-00001\">10.2165/00003088-198207020-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7039926/\">https://pubmed.ncbi.nlm.nih.gov/7039926</a></p></li><li><p>Anderson, SM, et al., &amp; Patel, RV (2011). Intravenous N-acetylcysteine in the prevention of contrast media-induced nephropathy. <i>The Annals of pharmacotherapy</i> 45(1) 101–107. DOI:<a href=\"https://doi.org/10.1345/aph.1P275\">10.1345/aph.1P275</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21205947/\">https://pubmed.ncbi.nlm.nih.gov/21205947</a></p></li><li><p>Fayed, MS, et al., &amp; Coles, LD (2023). Population Pharmacokinetic Model of N-Acetylcysteine During Periods of Recurrent Hypoglycemia in Healthy Volunteers. <i>Clinical pharmacology in drug development</i> 12(12) 1234–1240. DOI:<a href=\"https://doi.org/10.1002/cpdd.1338\">10.1002/cpdd.1338</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37937383/\">https://pubmed.ncbi.nlm.nih.gov/37937383</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V03AB23 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Acetylcysteine;
